Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of MXN 2.39 trillion. The enterprise value is 2.70 trillion.

Market Cap	2.39T
Enterprise Value	2.70T

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	Jun 13, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.28%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 19.57.

PE Ratio	19.57
Forward PE	n/a
PS Ratio	4.06
PB Ratio	6.12
P/TBV Ratio	n/a
P/FCF Ratio	11.86
P/OCF Ratio	11.26
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.96, with an EV/FCF ratio of 13.43.

EV / Earnings	22.16
EV / Sales	4.81
EV / EBITDA	9.96
EV / EBIT	12.63
EV / FCF	13.43

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.31.

Current Ratio	1.37
Quick Ratio	1.06
Debt / Equity	1.31
Debt / EBITDA	1.80
Debt / FCF	2.53
Interest Coverage	11.14

Financial Efficiency

Return on equity (ROE) is 32.66% and return on invested capital (ROIC) is 15.79%.

Return on Equity (ROE)	32.66%
Return on Assets (ROA)	12.14%
Return on Invested Capital (ROIC)	15.79%
Return on Capital Employed (ROCE)	24.84%
Revenue Per Employee	33.37M
Profits Per Employee	6.93M
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.45

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +70.44% in the last 52 weeks. The beta is 0.34, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	+70.44%
50-Day Moving Average	2,170.64
200-Day Moving Average	1,831.64
Relative Strength Index (RSI)	27.51
Average Volume (20 Days)	996

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.05

Income Statement

In the last 12 months, Gilead Sciences had revenue of MXN 587.31 billion and earned 121.92 billion in profits. Earnings per share was 96.69.

Revenue	587.31B
Gross Profit	459.79B
Operating Income	223.83B
Pretax Income	139.50B
Net Income	121.92B
EBITDA	280.50B
EBIT	223.83B
Earnings Per Share (EPS)	96.69

Full Income Statement

Balance Sheet

The company has 178.04 billion in cash and 509.99 billion in debt, giving a net cash position of -331.95 billion.

Cash & Cash Equivalents	178.04B
Total Debt	509.99B
Net Cash	-331.95B
Net Cash Per Share	n/a
Equity (Book Value)	389.93B
Book Value Per Share	314.58
Working Capital	93.14B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 211.87 billion and capital expenditures -10.67 billion, giving a free cash flow of 201.20 billion.

Operating Cash Flow	211.87B
Capital Expenditures	-10.67B
Free Cash Flow	201.20B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.29%, with operating and profit margins of 38.11% and 20.76%.

Gross Margin	78.29%
Operating Margin	38.11%
Pretax Margin	23.75%
Profit Margin	20.76%
EBITDA Margin	47.76%
EBIT Margin	38.11%
FCF Margin	34.26%

Dividends & Yields

This stock pays an annual dividend of 60.82, which amounts to a dividend yield of 3.18%.

Dividend Per Share	60.82
Dividend Yield	3.18%
Dividend Growth (YoY)	17.60%
Years of Dividend Growth	1
Payout Ratio	66.02%
Buyback Yield	-0.28%
Shareholder Yield	2.90%
Earnings Yield	5.11%
FCF Yield	8.43%

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.19.

Altman Z-Score	3.19
Piotroski F-Score	n/a